Shanghai Haohai Biological Technology Co., Ltd.
6826.HK · Healthcare · Biotechnology · Valued as of 2026-11-03 · Statements 2025-12-31
How Each Value Is Built
The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.
What it is worth
EPV + Growth
892.22M USD
what the normal year's earnings are worth for ever, plus growth that pays
Profit
569.92M USD
15 years of cash the shareholders can take out, and the equity left at year 15
FCFF
845.05M USD
15 years of cash for shareholders and lenders, less what is owed
Average Intrinsic Value
769.06M USD
The plain average of EPV, Profit and FCFF
Against the price
Market Cap
448.20M USD
the price on the date above times the shares
Intrinsic Value ÷ Market Cap
1.72×
the ratio the screener ranks by
Margin of Safety
+41.7%
1 − Market Cap / Average Intrinsic Value
Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.
EPV of the Operations (NOPAT over WACC)
604.77M USD
Net cash today
+287.45M USD
Growth Value
0 USD
Value
892.22M USD
①EPV (earnings power value)
604.77M USD②Net Cash Today
287.45M USD③Growth Value
0 USDMarket value
The price on the date above times the shares.
Value vs market
1 minus the market cap as a share of the value.
①Present Value of the 15 Years of FCFE
256.19M USD②Equity at Year 15, Today
313.73M USDMarket value
The price on the date above times the shares.
Value vs market
1 minus the market cap as a share of the value.
①Present Value of the 15 Years of FCFF
326.05M USD②Invested Capital at Year 15, Today
231.56M USD③Net Cash Today
287.45M USDMarket value
The price on the date above times the shares.
Value vs market
1 minus the market cap as a share of the value.
The Rates and the Capital the Values Read
The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.
The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.
The tax the interest saves.
The interest the company paid: EBIT is the profit before tax plus the interest.
What the lenders are paid a year after the tax the interest saves.
The part of the capital the lenders put in, at market value.
Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.
Total Assets 966.41M USD − Total Liabilities 162.20M USD = Book Value Today 804.21M USD
Total Debt 65.31M USD − Cash and Short-Term Investments 352.75M USD = Net Debt Today -287.45M USD
The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.
Market Data
The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.
Share price
15.69 HKD
Enterprise value
1.66B HKD
the provider's own figure
EV / EBITDA
5.36×
Price / book
0.57×
the provider's book
Price / earnings
21.18×
Return on equity
2.1%
the provider's figure, not this page's
Profit margin
6.6%
Revenue growth
-11.4%
Analyst target, mean
—
Analysts
—
opinions in the consensus
Financial Statements
The annual lines the screener holds, year by year, in USD at each period's rate; the figures this valuation read are in its calculation above.